Accomplished as noted under I 2. The National Institutes of Health and industry should support the continued evaluation of the use and appropriate dose of intravenous immunoglobulins for indications where its benefit requires further delineation, and the results of these evaluations should be rapidly disseminated to the public. Industry should work with the Food and Drug Administration to expand capacity sufficiently to meet anticipated demand for plasma derivatives. Industry members have announced plans to expand capacity. Industry and government should jointly explore the antitrust implications of efforts to share data in order to prevent shortages.
Major concern is in projection of demand.